Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by Oppenheimer

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “outperform” rating reiterated by research analysts at Oppenheimer in a report released on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock.

Other analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Thursday, July 11th.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $0.94 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.77 and a current ratio of 2.77. Gain Therapeutics has a one year low of $0.89 and a one year high of $5.33. The firm has a market capitalization of $16.90 million, a P/E ratio of -0.62 and a beta of 0.35. The company’s fifty day moving average is $1.31 and its two-hundred day moving average is $2.83.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). Analysts forecast that Gain Therapeutics will post -1.03 EPS for the current fiscal year.

Insider Activity

In other news, Chairman Khalid Islam bought 50,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chairman now owns 50,000 shares of the company’s stock, valued at $50,000. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders purchased 81,400 shares of company stock worth $85,284. 11.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GANX. Renaissance Technologies LLC increased its position in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after acquiring an additional 72,000 shares during the last quarter. Warberg Asset Management LLC purchased a new stake in Gain Therapeutics during the 2nd quarter worth approximately $66,000. Finally, Hohimer Wealth Management LLC acquired a new position in shares of Gain Therapeutics in the 2nd quarter valued at approximately $422,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.